- BioCina Pty Ltd. has partnered with Centivax, Inc. to support the development of a universal influenza vaccine known as Cent-Flu.
- The collaboration involves cell line development, cell banking, and plasmid DNA manufacture, aiming for First-in-Human clinical trials.
BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), has announced a partnership with Centivax, Inc. The collaboration aims to develop Centivax’s universal influenza vaccine, Cent-Flu, which utilises a proprietary mixture of 22 unique mRNA transcripts delivered via lipid nanoparticles.
This partnership will encompass various aspects of vaccine production, including cell line development, cell banking, and plasmid DNA manufacturing. The goal is to progress Cent-Flu towards First-in-Human clinical trials, demonstrating its potential to protect against both current and future influenza strains.
Mark W. Womack, Chief Executive Officer of BioCina, stated, “We’re privileged to support Centivax’s breakthrough approach to sustained flu prevention and we couldn’t be more excited to be their partner of choice to initiate cGMP manufacturing.” He emphasised the opportunity for BioCina to leverage its capabilities in cell line development and plasmid production.
Centivax’s CEO, Jacob Glanville, expressed enthusiasm about the partnership, highlighting BioCina’s expertise and state-of-the-art facilities. He noted that this collaboration would ensure high standards in vaccine production, a critical step toward making their universal influenza vaccine widely available.
Overview of outsourcing trends 
